Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; hepatitis b immunoglobulin, quantity: 100 iu - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - indications as at 8 august 2002 : hepatitis b immunoglobulin is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive material or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin is also indicated for prophylaxis in infants born to hbsag-positive mothers. hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 50 mg/ml; cytomegalovirus immunoglobulin, quantity: 1500000 u - injection, intravenous infusion - excipient ingredients: water for injections; human immunoglobulin a; maltose - cmv immunoglobulin-vf is indicated for the prevention of cmv infection following bone marrow and renal transplants. specifically, the product is indicated when the recipient is seronegative for cmv and receives a graft from a cmv positive donor. cmv immunoglobulin-vf may also be a helpful adjunct to therapy in patients with established cmv infection, e.g. cmv pneumonitis.

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - human papillomavirus (unii: 23cvl7wf4j) (human papillomavirus - unii:23cvl7wf4j) - law of similars - use according to standard homeopathic indications law of similars - use according to standard homeopathic indications

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

human bioplazma llc, hungary - albumin human - solution - 20 %

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - adenovirus (type 16) 12x, 30x, 60x condylomata acuminata 12x, 30x, 60x papillomavirus 30x, 60x - for the temporary relief of itching, burning, or irritated skin.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Kenya - English - Pharmacy and Poisons Board

human albumin 20% - infusion - human albumin 20% - albumin

Israel - English - Ministry of Health

csl behring ltd., israel - human fibrinogen - powder for solution for inj/inf - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - plasma protein containing at least 95% human albumin - solution for infusion - 50 gram(s)/litre - blood substitutes and plasma protein fractions; albumin - plasma substitutes and plasma protein fractions - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.

Ireland - English - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - plasma protein containing at least 95% human albumin - solution for infusion - 200 gram(s)/litre - blood substitutes and plasma protein fractions; albumin - plasma substitutes and plasma protein fractions - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate